611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line

NurseWise 24-Hour Crisis Line


611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...

Basic InformationLatest News
Lack of Training Linked to Cancer Patient Caregiver BurdenMelanoma Isn't the Only Serious Skin CancerMany With Cancer Hospitalized, Undergo Imaging at End of Life$100 Sweetens the Pot for a ColonoscopyVascular Targeted Photodynamic Tx Aids Low-Risk Prostate CancerObesity in Teen Years Tied to Colon Cancer Risk in AdulthoodASCO Addresses Cancer Drug PricingSenator McCain Faces a Tough Cancer FoeMore Patients OK'd for Cancer Trials Under Obamacare: StudyInsured, But Still Barred From Top-Tier Cancer CentersMany Terminal Cancer Patients Remain in DenialSingle-Dose PCV13 Immunogenic, Safe in Pediatric OncologyDoctors' Group Offers Ideas for Easing Cancer Costs'Nipple-Sparing' Mastectomies Don't Raise Odds of Cancer's Return: StudyNerlynx Approved to Help Prevent Breast Cancer's ReturnLittle Evidence That Vasectomy Raises Prostate Cancer RiskWait-and-Scan Strategy Feasible for Head, Neck ParagangliomaHigher Nodal Yield Tied to Lower Mortality in Oral Cavity CancerChange to Cervical Screening Guidelines Impacted ChlamydiaBlood Test for Early Detection of Pancreatic Cancer Feasible'Observation' Best Option for Most Low-Risk Prostate CancerAre Big Men More Prone to Aggressive Prostate Cancer?Rivaroxaban OK for Stroke Prevention in Cancer PatientsNew Test May Help Spot Pancreatic Cancer EarlyDecisional Regret Doesn't Differ by Treatment in Prostate CancerEasier Colon Exam Boosts Screening, But Insurers May Not PayParkinson's Patients Deemed at Higher Risk of MelanomaMost Breast Cancer Patients Have Help Choosing TreatmentsFor Holocaust Survivors, Raised Risk of CancerParkinson's Disease and Melanoma May Occur Together, Study FindsGermline Mutations Up in Men With Prostate CA, One Other CACancer Deaths Higher in Rural America, CDC ReportsFDA Widens Access to 'Cooling Cap' to Stop Hair Loss in Cancer PatientsNivolumab Rx Beyond Progression Beneficial in MelanomaMany Women Have Questions, Concerns About TamoxifenMelanoma Diagnoses Can Vary Widely Among PathologistsMany Women Mistaken on 'Side Effects' of Breast Cancer DrugMelanoma Biopsy Results Can Differ, Worrying PatientsNew Microscope Scans Breast Tumors During SurgeryCan You Recognize the Signs of Skin Cancer?Reduced Cancer-Independent Life Expectancy in Head, Neck CancerMore Breast Cancers Diagnosed at Late Stage With Medicaid CutsSimilar Skin Cancer Incidence Seen With TeledermatologyMedicaid Cuts Tied to Delayed Breast Cancer DiagnosesACOG: Shared Decision-Making Key to Breast Cancer ScreeningDrug, Herb Interactions Frequent for Cancer PatientsMany With Advanced Cancer Want Secondary Germline Findings InfoSecondhand Smoke Still Plagues Some Cancer SurvivorsBig Gap in Cancer Deaths Between Rich, Poor CountriesMany Doctors Silent on Cost of Cancer Care
LinksBook ReviewsSelf-Help Groups
Related Topics

Medical Disorders
Pain Management

HPV Vaccine May Also Prevent Cancers Affecting Men

HealthDay News
by -- Robert Preidt
Updated: May 18th 2017

new article illustration

THURSDAY, May 18, 2017 (HealthDay News) -- The same vaccine that cuts the risk of cervical cancer in women might also lower the chances of head and neck cancers in men, new research suggests.

In addition to being linked to cervical cancer, the human papillomavirus (HPV) can cause cancers in the back of the throat, in an area known as the oropharynx. HPV is linked with about 70 percent of these types of cancers in the United States, and the rates of these cancers are rising dramatically, according to the U.S. Centers for Disease Control and Prevention.

The U.S. Food and Drug Administration has approved HPV vaccines for prevention of cervical, vulvar, vaginal and anal cancers in women, and anal cancers in men. However, the HPV vaccine hasn't been FDA-approved for prevention of head and neck cancers, because the vaccines have not been evaluated in clinical trials for that purpose.

"We don't know if there's a potential solution to these rising rates already existing on [drug] shelves," explained study author Dr. Maura Gillison. She is a professor of thoracic/head and neck medical oncology at the University of Texas MD Anderson Cancer Center.

"In the absence of that gold-standard clinical trial, we looked at data from a study that we've been conducting in my lab to address the question as to whether or not existing HPV vaccines could be altering oral HPV infections in the U.S. population," she explained in a Cancer Center news release.

The analysis of data from more than 2,600 Americans, aged 18 to 33, revealed that those who had received HPV vaccination were 88 percent less likely to have oral HPV infections than those who were not vaccinated.

Previous research has shown that HPV-related head and neck cancers are more common in men than women, so Gillison and her colleagues examined whether vaccination was associated with a reduced prevalence of oral HPV infection in men.

"When we compared the prevalence in vaccinated men to non-vaccinated men, we didn't detect any infections in vaccinated men. The data suggests that the vaccine may be reducing the prevalence of those infections by as high as 100 percent," Gillison said.

"We also wanted to determine, accounting for the low rates of vaccination, what proportion of infections could have been prevented," she said.

"We found that just under one million people would have HPV infections in this age group, but, unfortunately, because of low uptake of the vaccine, the burden of infection had only been reduced by 17 percent overall, and only 7 percent in men. We hope the burden of infection will decrease over time with increased vaccination," Gillison said.

The study, conducted while Gillison was at Ohio State University, is to be presented in June at the American Society of Clinical Oncology annual meeting, in Chicago. Research presented at medical meetings should be viewed as preliminary until published in a peer-reviewed journal.

More information

The Oral Cancer Foundation has more on HPV.